VERV — Verve Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $555.23m
- -$68.72m
- $11.76m
- 51
- 17
- 18
- 18
Annual cashflow statement for Verve Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -19.3 | -45.7 | -120 | -157 | -200 |
| Depreciation | |||||
| Non-Cash Items | 9.09 | 6.47 | 43.8 | 23.9 | 27.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.66 | 2.64 | -2.91 | 8.38 | 17.7 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.44 | -35.3 | -77.9 | -122 | -150 |
| Capital Expenditures | -1.86 | -3.42 | -4.36 | -13.2 | -9.28 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -10.9 | -47.7 | -235 | -143 | 37 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -12.8 | -51.1 | -239 | -156 | 27.7 |
| Financing Cash Flow Items | — | — | -2.85 | -0.783 | -0.458 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18 | 92.6 | 377 | 329 | 213 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.25 | 6.24 | 60.1 | 50.7 | 90.7 |